SNY

Sanofi
$45.54
+1.54 (+3.50%)
Mkt Cap 110.48B
Volume 2,849,483
52W Range 40.89-52.68
Sector Healthcare
Beta 0.28
EPS (TTM) 1.94
P/E Ratio 23.47
Revenue (TTM) 47.35B
Rev Growth (5Y) +4.6%
EPS Growth (5Y) -8.2%
AlphaVal · Fair Value
What we estimate one share is worth
$61.35
Undervalued moderate signal
25.8% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B-
Stable Earnings Power
65.2 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 46.72B 44.29B 41.62B 40.56B 39.17B 37.37B 37.63B 35.68B 36.22B 34.70B 34.86B 32.00B
Net Income 7.81B 5.56B 5.40B 8.37B 6.22B 12.29B 2.75B 4.31B 8.42B 4.71B 4.29B 4.39B
EPS 3.20 2.19 2.15 3.19 2.49 4.91 1.14 1.73 1.50 1.83 1.64 1.67
Free Cash Flow 10.14B 5.89B 8.64B 8.32B 8.48B 5.33B 5.93B 3.57B 5.42B 5.75B 6.15B 6.13B
FCF / Share 4.16 2.35 3.45 3.32 3.38 2.13 2.37 1.43 2.16 2.24 2.35 2.33
Operating CF 12.13B 9.08B 10.26B 10.53B 10.52B 7.45B 7.74B 5.55B 7.38B 7.84B 8.92B 7.69B
Total Assets 126.81B 132.80B 126.46B 126.72B 120.24B 114.41B 112.74B 111.41B 99.81B 104.67B 102.32B 97.39B
Total Debt 20.33B 17.91B 18.70B 21.21B 22.41B 23.68B 25.93B 24.64B 15.60B 18.58B 16.55B 14.81B
Cash & Equiv 7.66B 7.44B 8.71B 12.74B 10.10B 13.91B 9.74B 6.92B 10.31B 10.27B 9.15B 7.34B
Book Value 71.38B 77.51B 74.04B 74.78B 68.68B 63.11B 58.93B 58.88B 58.07B 57.55B 58.05B 56.12B
Return on Equity 0.11 0.07 0.07 0.11 0.09 0.19 0.05 0.07 0.14 0.08 0.07 0.08
SNY News
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
Jul 23, 2026 10:32 PM · wsj.com
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
Jul 23, 2026 09:30 PM · globenewswire.com
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Jul 21, 2026 08:00 AM · globenewswire.com
AI Bubble Risks Make Dividend Stocks Attractive Again
Jul 18, 2026 09:03 AM · seekingalpha.com
Aqemia and Sanofi Expand Their Research Collaboration
Jul 17, 2026 02:30 AM · businesswire.com
3 High-Yield Dividend Stocks to Buy and Hold
Jul 16, 2026 09:00 PM · fool.com
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Jul 10, 2026 04:35 AM · globenewswire.com
US FDA approves Sanofi's wearable injector form of blood cancer drug
Jul 10, 2026 04:22 AM · reuters.com
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
Jul 08, 2026 02:00 AM · reuters.com
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Jul 01, 2026 06:26 AM · zacks.com